Phathom Pharmaceuticals Q3 2026 net revenues climb 71% year over year to $84.7 million
PHAT•Phathom Pharmaceuticals reported Q3 2026 net revenues of $84.7 million, up 71% year over year, and reaffirmed its 2026 revenue and non-GAAP operating expense guidance.
1. Quarterly results
Phathom Pharmaceuticals’ Q3 2026 net revenues climbed 71% year over year to $84.7 million. Operating profit excluding stock-based compensation remained positive for a second consecutive quarter, and net cash generated totaled $2.1 million.
2. Prescriptions and guidance
Covered VOQUEZNA prescriptions rose approximately 19% from Q2 2026 to approximately 248,000. The company reaffirmed its 2026 net revenue guidance of $310 million to $325 million and non-GAAP operating expense guidance of $235 million to $245 million.
